Skip to Content

Long-term treatment of ovarian cancer with PARP-inhibitor

Poly(ADP-ribose) polymerase inhibitors (PARPi) are a new class of maintenance treatment approved for patients with newly diagnosed, advanced or recurrent ovarian cancer following a response to platinum-based chemotherapy.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top